| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2798825 | Diabetes Research and Clinical Practice | 2007 | 4 Pages |
Abstract
To investigate the effects of sulfonylurea receptor 1 (SUR1) exon 33 (TCC → GCC, S1369A) polymorphism on responsiveness to gliclazide. About 115 patients with type 2 diabetes were treated with gliclazide for 8 weeks. SUR1 genotypes were tested by Taqman-PCR. After gliclazide treatment, there was association between T/G polymorphism and decrease of HbA1c. G carriers were more sensitive to gliclazide and the decrease of HbA1c was more significant than TT genotype (TT, 0.76% ± 1.70%; TG + GG, 1.60% ± 1.39%, P = 0.044). The polymorphism of SUR1S1369A was associated with the therapeutic efficacy of gliclazide.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Huijuan Zhang, Xiaomin Liu, Hongyu Kuang, Ran Yi, Houxun Xing,